SINOMAB BIO-B (03681) soared over 18% intraday, hitting HK$2.42 with turnover reaching HK$50.8039 million. The biopharma firm voluntarily withdrew its Biologics License Application (BLA) for Sucirasertib (SM03) in treating rheumatoid arthritis (RA) following consultations with China's Center for Drug Evaluation (CDE).
This strategic decision stems from an internal assessment indicating supplemental early-phase efficacy data is required for BLA approval. SINOMAB maintains confidence in Sucirasertib's eventual approval in China and has initiated new clinical development plans targeting systemic lupus erythematosus (SLE) treatment.
Notably, breakthrough preclinical in-vivo results for SM03 - the world's first anti-CD22 monoclonal antibody - demonstrate its unique dual mechanism: modulating autoimmune networks through B-cell interaction while providing organ damage protection. This positions SM03 to address critical unmet needs in SLE management, particularly concerning long-term medication safety risks and absence of organ protection benefits. The therapy could potentially deliver safer, more effective treatment alternatives for global patients.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。